Relative Risk of Onset of Cancer from the Cholesterol Treatment Trialists’ (CTT) Meta-Analysis of Statin Trials, According to Year of Onset Risk ratios.

Slides:

Advertisements

Similar presentations

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Advertisements

Clinical Outcomes with Newer Antihyperglycemic Agents

Glynn RJ, et al. N Engl J Med 2009 Mar 29 [Epub ahead of print]

C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Use of Inhaled Corticosteroids and the Risk.

Date of download: 6/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of Homocysteine-Lowering With Folic Acid.

Clinical Outcomes with Newer Antihyperglycemic Agents

The SPRINT Research Group

Copyright © 2006 American Medical Association. All rights reserved.

Arch Intern Med. 2004;164(13): doi: /archinte Figure Legend:

Copyright © 2009 American Medical Association. All rights reserved.

Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study

Copyright © 2011 American Medical Association. All rights reserved.

Figure 1. Meta-analysis of prospective biomarker studies examining associations between eicosapentaenoic acid (EPA) and total, low-, and high-grade prostate.

Copyright © 2011 American Medical Association. All rights reserved.

Predicted 5-year benefits of LDL cholesterol reductions with statin treatment at different levels of risk. (A) Major vascular events, and (B) vascular.

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

Copyright © 2012 American Medical Association. All rights reserved.

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

Figure e-1. Further Meta-analysis of previously reported PD and mtDNA haplogroup associations and the data from this study. Meta-analysis of published.

Thomas F. O’Donnell, MD, Joseph Lau, MD Journal of Vascular Surgery

A Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long-Chain Omega-3 Fatty Acids.

TNT: Baseline and final LDL cholesterol levels

A Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long-Chain Omega-3 Fatty Acids.

Coffee Consumption and Risk of Liver Cancer: A Meta-Analysis

Results of random-effects meta-analysis of association between use of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers and.

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Use of Targeted Temperature Management After Out-of-hospital Cardiac Arrest: A Meta- Analysis of Randomized Controlled Trials Ahmed Mahmoud, MD, Islam.

George E. Kikano, MD, Marie T. Brown, MD Mayo Clinic Proceedings

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta- analysis of individual participant data from randomised trials

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

Thomas F. O’Donnell, MD, Joseph Lau, MD Journal of Vascular Surgery

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

David J.A. Jenkins et al. JACC 2018;71:

Yousef Rezaei, MD American Journal of Kidney Diseases

Effect of confidence interval reduction to demonstrate a true difference in means. Effect of confidence interval reduction to demonstrate a true difference.

Potential mechanisms whereby statins may reduce the risk of stroke

Hepatic Vein Pressure Gradient Reduction and Prevention of Variceal Bleeding in Cirrhosis: A Systematic Review Gennaro D’Amico, Juan Carlos Garcia-Pagan,

Daan Kromhout, et al. NEJM epub August 29, 2010

HOPE-3 Trial design: Patients without known cardiovascular disease, and with an intermediate risk of cardiovascular events, were randomized in a 2 x 2.

Berger JS, et al. JAMA 2009;301:

Characteristics of the Patients at Baseline*

Volume 375, Issue 9719, Pages (March 2010)

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

Cause of death Treatment-arm events, % (n=45 054)

Drug-eluting stents versus coronary artery bypass grafting for the treatment of coronary artery disease: A meta-analysis of randomized and nonrandomized.

Relative Risk of Myopathy Associated with Selected Baseline Characteristics among 6031 Participants Assigned to 80 mg of Simvastatin Daily in SEARCH The.

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28.

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: Duminda N Wijeysundera, MD, Jennifer S Naik, MD, W Scott Beattie, MD,

Characteristics of Large Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. et al. JACC 2008 Aug 20 [Epub ahead of print]

Volume 73, Issue 8, Pages (April 2008)

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised.

Risk of having any adverse effects with supplements compared with placebo. Risk of having any adverse effects with supplements compared with placebo. Stratified.

The ACCORD Study Group. NEJM 2010; Epub March 14

Keratinocyte growth factor (KGF) versus no KGF for the reduction of severe oral mucositis in patients receiving treatment for cancer or undergoing haematopoietic.

Davide Capodanno et al. JCIN 2009;2:

Volume 59, Issue 5, Pages (May 2001)

Pooled risk with 95% CI of ACM (A) and CVD risk (B) for the highest vs

M. Hassan Murad, MD, MPH, David N. Flynn, BS, Mohamed B

Change in the regular use of inhaled corticosteroids (as a single inhaler or in combination; any use in the last 12 months) in participants with persistent.

Effect of randomized treatment on all renal events (top) and the composite of all renal events, macrovascular events, or all-cause mortality (bottom) according.

Relative risks of colon cancer in prospective cohort studies, comparing the highest with the lowest category of heme iron consumption. Relative risks of.

Cryotherapy versus no cryotherapy for the reduction of severe oral mucositis in patients receiving treatment for cancer or undergoing haematopoietic stem.

Pooled estimate of relative risk and 95% CIs of colorectal cancer associated with metformin therapy based on four studies comprising 107,961 diabetic patients.

Forest plot of platelet-rich plasma (PRP) versus control on tendinopathy pain. Forest plot of platelet-rich plasma (PRP) versus control on tendinopathy.

Forest plot for one-study removed sensitivity analysis of platelet-rich plasma (PRP) versus control on tendinopathy pain. Forest plot for one-study removed.

Presentation transcript:

Relative Risk of Onset of Cancer from the Cholesterol Treatment Trialists’ (CTT) Meta-Analysis of Statin Trials, According to Year of Onset Risk ratios are reported for participants at risk for a first cancer after randomization. Squares with horizontal lines are risk ratios and the corresponding 99% confidence intervals, with the sizes of the squares proportional to the amount of statistical information. The overall risk ratio (diamond) was 1.00 (95% confidence interval, 0.95 to 1.04). The chi-square statistic for trend in the risk ratio for all trials combined was 0.69 (P = 0.40). The data include published data from 13 trials and unpublished data from the 14th trial in the CTT meta-analysis. Peto R et al. N Engl J Med 2008 Sep 2 [Epub ahead of print]

Numbers of Persons with Onset of Fatal or Nonfatal Cancer in the SEAS Trial and in SHARP and IMPROVE-IT Peto R et al. N Engl J Med 2008 Sep 2 [Epub ahead of print]

Relative Risk of Onset of Cancer in the SEAS Trial and in SHARP and IMPROVE-IT, According to Year of Onset Squares with horizontal lines are risk ratios and the corresponding 99% confidence intervals, with the sizes of the squares proportional to the amount of statistical information. The overall risk ratio (diamond) for the SEAS study was 1.55 (95% confidence interval [CI], 1.13 to 2.12) and for SHARP and IMPROVE-IT combined was 0.96 (95% CI, 0.82 to 1.12). The numbers of patients (in either treatment group) with a first cancer recorded during each year (0 to 1, >1 to 2, >2 to 3, and >3) are 201, 194, 115, and 44, respectively, for SHARP and 71, 14, 0, and 0, respectively, for IMPROVE-IT. The chi-square statistic for heterogeneity between risk ratios in SHARP and IMPROVE-IT was 0.01 (P = 0.91). The chi-square statistic for trend over time in the risk ratio for SEAS was 0.00 (P = 1.00), for SHARP and IMPROVE-IT combined was 0.04 (P = 0.84), and for all three trials combined was 0.52 (P = 0.47). Peto R et al. N Engl J Med 2008 Sep 2 [Epub ahead of print]

Relative Risk of Onset of Cancer in the SEAS Trial and in SHARP and IMPROVE-IT, According to Recorded Outcome Squares with horizontal lines are risk ratios and the corresponding 99% confidence intervals, with the sizes of the squares proportional to the amount of statistical information; the diamonds indicate the overall risk ratios and 95% confidence interval. The overall risk ratio (diamond) for the SEAS study was 1.55 (95% confidence interval [CI], 1.13 to 2.12) and for SHARP and IMPROVE-IT combined was 0.96 (95% CI, 0.82 to 1.12). The chi-square statistic for the difference between the risk ratios from the SEAS study and from SHARP and IMPROVE-IT combined was 7.5 (P = 0.006). Peto R et al. N Engl J Med 2008 Sep 2 [Epub ahead of print]

Numbers of Deaths from Cancer in the SEAS Trial and in SHARP and IMPROVE-IT Peto R et al. N Engl J Med 2008 Sep 2 [Epub ahead of print]

Relative Risk of Death from Cancer in the SEAS Trial and in SHARP and IMPROVE-IT, According to Year of Onset Squares with horizontal lines are risk ratios and the corresponding 99% confidence intervals, with the sizes of the squares proportional to the amount of statistical information. The overall risk ratio (diamond) for the SEAS study was 1.78 (95% confidence interval [CI], 1.03 to 3.11) and for SHARP and IMPROVE-IT combined was 1.34 (95% CI, 0.98 to 1.84). The chi-square statistic for heterogeneity between risk ratios in SHARP and IMPROVE-IT was 0.53 (P = 0.47). The chi-square statistic for trend in the risk ratio for SEAS was 4.45 (P = 0.03), for SHARP and IMPROVE-IT combined was 1.35 (P = 0.25), and for all three trials combined was 0.38 (P = 0.54). Unlike the 99% confidence intervals in Figure 3, the 95% confidence intervals in this figure do not make any correction for the data-dependent decision to present data on death from cancer separately. Peto R et al. N Engl J Med 2008 Sep 2 [Epub ahead of print]